The microbiome is implicated in numerous diseases and health conditions. Learn how Kaleido is leading a differentiated approach to translating the promise of the microbiome into solutions for patients.
Using our proprietary product platform, we have created a library of more than 1,500 MMT candidates. Our MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Our initial MMT candidates are targeted glycans and our library of MMTs is rapidly growing. Our MMTs are novel, proprietary compounds that are orally administered, selectively metabolized in the gut and have limited systemic exposure. Our MMTs are also related to a class that is generally recognized as safe or GRAS. We are advancing a pipeline of MMTs in multiple therapeutic areas, click here to learn more.
The microbiome produces metabolites that are essential for human health. In many ways the microbiome operates as another human organ, metabolizing nutrients that are otherwise unavailable to humans and interacting with many parts of the body through biochemical signals. Kaleido’s MMTs are designed to drive the function and distribution of the microbiome’s existing microbes. MMTs work through one or more mechanisms of action: increasing the production of metabolites, decreasing the production of metabolites, and advantaging or disadvantaging certain species in the microbiome community.
At Kaleido, we are breaking the mold of traditional discovery and development by using a human-centric approach to allow us to more effectively advance optimized, data-rich product candidates. We conduct ex vivo screening of microbiomes from healthy volunteers and ex vivo testing of patient microbiomes, which enables the integration of human data at the earliest stages. We also have been able to advance our MMTs into human clinical studies under regulations supporting research with food. After conducting these studies, we determine whether or not to pursue an MMT as a drug product and file an IND, or pursue non-drug development opportunities. Our approach has the potential to be faster and more cost efficient than traditional discovery and development. We plan to initiate our first Phase 2 clinical trial under IND for one of our MMT candidates in the first half of 2019, approximately two years after conducting our first ex vivo screening.
The human microbiome is the community of more than 30 trillion microbes, single-cell organisms that include bacteria, viruses, archaea and fungi, which reside on and inside the human body. Over the last decade research has increased exponentially on the impact the microbiome has on human health, including cardiovascular disease, cancer, diabetes, Parkinson’s disease and allergies. This highly complex microbial ecosystem has been referred to as a “newly discovered organ.” Many other human organs command tens of billions of dollars for therapeutics that treat disease by modulating physiology. From a therapeutic perspective, the microbiome organ remains a largely untapped frontier in healthcare.
|October 6-10, 2019||Chemical Modulation of the Gut Microbiome Alleviates Chemotherapy-Induced Toxicity||Keystone Symposia on Molecular and Cellular Biology I Microbiome: Therapeutic Implications||Click here|
|October 2-6, 2019||Novel Glycans Reduce Carbapenem-resistant Enterobacteriaceae (CRE) and Vancomycin-resistant Enterococcus (VRE) Colonization in an Ex Vivo Assay by Supporting Growth of Commensal Microbiota at the Expense of Multidrug-Resistant (MDR) Organisms||IDWeek 2019™||Click here|
|September 3-6, 2019||An Open-Label, Single-Arm Clinical Study to Evaluate Safety and Tolerability of KB195, A Novel Glycan, in Patients with Urea Cycle Disorders||SSIEM/ Society for the Study of Inborn Errors of Metabolism Annual Symposium||Click here|
|April 12, 2019||Identification of Novel Glycans That Target Gut Microbiota-Associated Ammonia Production||EASL | The International Liver Congress™ 2019||Click here|
|April 7, 2019||KB195, a Novel Glycan, Modulates Ammonia Metabolism in Healthy Subjects and in Microbiome Samples Collected From Patients With Urea Cycle Disorders||Society for Inherited Metabolic Disorders (SIMD), 41st Annual Meeting||Click here|
|March 12, 2019||Developing a Drug Discovery Platform to Target Gut Microbiota-Associated Ammonia Production||Keystone Symposia, Microbiome: Chemical Mechanisms and Biological Consequences||Click here|
|September 18, 2018||Microbiome Metabolic Therapies (MMTs) reduce pathogen colonization in ex vivo testing of intensive care unit patient microbiomes||EMBO | EMBL Symposium: The Human Microbiome||Click here|
Viewing these publications requires you to leave Kaleido Biosciences’ website. Kaleido assumes no responsibility for the
information, statements or other content you may encounter on third-party websites.
|November 25, 2014||A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota||Journal of Molecular Biology||Click here|
|April 24, 2013||Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk||New England Journal of Medicine||Click here|
|April 11, 2012||How glycan metabolism shapes the human gut microbiota||Nature Reviews Microbiology||Click here|
|March 11, 2006||Effect of lactulose and Saccharomyces boulardii administration on the colonic urea‐nitrogen metabolism and the bifidobacteria concentration in healthy human subjects||Alimentary Pharmacology & Therapeutics||Click here|